Glomerular filtration rate in patients with psoriasis treated with etanercept.
OBJECTIVE
To estimate the prevalence of chronic kidney disease (CKD) and evaluate renal function in patients with moderate-to-severe chronic plaque psoriasis treated with etanercept (an anti-tumour necrosis factor-α drug).


METHODS
This retrospective cohort study included patients with moderate-to-severe chronic plaque psoriasis. Kidney function was evaluated using estimated glomerular filtration rate (EGFR).


RESULTS
The prevalence of CKD at baseline was 3.9% (two of 51 patients). EGFR was unaffected by etanercept therapy (83.6 ± 23.9 at baseline vs 82.2 ± 21.6 ml/min per 1.73 m2after 6 months).


CONCLUSIONS
EGFR was unaffected by 6 months' etanercept treatment. Physicians should be aware of the risk of CKD when providing comprehensive care to patients with moderate-to-severe psoriasis.
Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy paolo.gisondi@univr.it.
Paolo
P
Gisondi
Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Giampiero
G
Girolomoni
Etanercept; glomerular filtration rate; psoriasis
Br J Dermatol. 2011 Nov;165(5):1037-43
21711339
Arch Dermatol Res. 2015 Dec;307(10):875-83
26358263
BMJ. 2013 Oct 15;347:f5961
24129480
Ann Intern Med. 1999 Mar 16;130(6):461-70
10075613
Br J Dermatol. 2015 Jul;173(1):146-54
25511692
Br J Dermatol. 2007 Jul;157(1):68-73
17553036
Ann Intern Med. 2003 Jul 15;139(2):137-47
12859163
Curr Opin Nephrol Hypertens. 2013 May;22(3):310-5
23571811
Br J Dermatol. 2010 Sep;163(3):586-92
20633008
J Eur Acad Dermatol Venereol. 2013 Jan;27(1):e30-41
22313340
G Ital Dermatol Venereol. 2013 Dec;148(6 Suppl 1):1-10
24675369
N Engl J Med. 2004 Sep 23;351(13):1296-305
15385656
J Am Acad Dermatol. 2012 Mar;66(3):369-75
22041254